CareDx (CDNA) to Release Earnings on Monday

by · The Markets Daily

CareDx (NASDAQ:CDNA – Get Free Report) will be releasing its earnings data after the market closes on Monday, November 4th. CareDx has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.37. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The company had revenue of $92.27 million for the quarter, compared to analyst estimates of $67.20 million. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Trading Down 2.0 %

CDNA stock opened at $22.39 on Monday. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -6.55 and a beta of 1.77. The firm has a 50 day moving average of $29.04 and a 200-day moving average of $20.25. CareDx has a 12-month low of $4.80 and a 12-month high of $34.84.

Insider Activity

In related news, insider Alexander L. Johnson sold 21,557 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total value of $702,327.06. Following the transaction, the insider now directly owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the transaction, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,561,179.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander L. Johnson sold 21,557 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,284,746.14. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock valued at $3,025,415 in the last ninety days. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

CDNA has been the topic of a number of research analyst reports. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. The Goldman Sachs Group raised their target price on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Craig Hallum boosted their price target on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company initiated coverage on CareDx in a report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price objective on the stock. Finally, BTIG Research upgraded CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a research note on Monday, August 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.60.

Read Our Latest Stock Report on CDNA

CareDx Company Profile

(Get Free Report)

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Recommended Stories